Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.
Michael DiIorioKevin KennedyJean W LiewMichael S PutmanEmily SirotichSebastian Eduardo SattuiGary FosterCarly HarrisonMaggie J LarchéMitchell LevineTarin T MoniLehana ThabaneSuleman BhanaWendy CostelloRebecca GraingerPedro M MachadoPhilip C RobinsonPaul SufkaZachary S WallaceJinoos YazdanyMonique Gore-MassyRichard A HowardMore A KodhekNadine LalondeLaura-Ann TomasellaJohn WallaceAkpabio AkpabioDeshiré Alpizar-RodriguezRichard P BeesleyFrancis BerenbaumInita BulinaEugenia Yupei ChockRichard ConwayAlí Duarte-GarcíaEimear DuffTamer A GheitaElizabeth R GraefEvelyn HsiehLina El KibbiDavid F L LiewChieh LoMichal NudelAman Dev SinghJasvinder A SinghNamrata SinghManuel Francisco Ugarte-GilJonathan S HausmannJulia F SimardJeffrey A SparksPublished in: RMD open (2022)
Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.